…that a specific metabolite of estrogen is more predictive of breast cancer risk than is the presence of the genetic markers BRCA1 and BRCA2?

This metabolite is 4-OH estrogen and has a greater binding affinity to the estrogen receptor than estradiol which is the primary estrogen produced from the ovary during the menstrual cycle. Women with this metabolite need to consider taking one of two different supplements:

1. DIM (Diindolylmethane) which will steer metabolism away from the 4-OH estrogen pathway that increases risk to the 2-OH estrogen pathway that reduces the risk. There are no side effects with this supplement.
2. DHEA which also steers metabolism down the 2-OH estrogen pathway and away from the 4-OH pathway. Dosages of DHEA in women should be kept at 5-10mg daily. DHEA does carry some side effects including acne